Biblioteca de los Sistemas de Salud de la OMS
Cambiar a la version en inglésCambiar a la version en francés
WHO Monographs on Selected Medicinal Plants - Volume 2
(358 pages)

Índice de contenido
Ver el documentoIntroduction
Ver el documentoGeneral technical notices
Ver el documentoRadix Althaeae
Ver el documentoHerba Andrographidis
Ver el documentoRadix Angelicae Sinensis
Ver el documentoFlos Calendulae
Ver el documentoFlos Caryophylli
Ver el documentoRhizoma Cimicifugae Racemosae
Ver el documentoFolium cum Flore Crataegi
Ver el documentoRadix Eleutherococci
Ver el documentoAetheroleum Eucalypti
Ver el documentoFolium Eucalypti
Ver el documentoCortex Frangulae
Ver el documentoFolium et Cortex Hamamelidis
Ver el documentoSemen Hippocastani
Ver el documentoHerba Hyperici
Ver el documentoAetheroleum Melaleucae Alternifoliae
Ver el documentoFolium Melissae
Ver el documentoAetheroleum Menthae Piperitae
Ver el documentoFolium Menthae Piperitae
Ver el documentoFolium Ocimi Sancti
Ver el documentoOleum Oenotherae Biennis
Ver el documentoRhizoma Piperis Methystici
Ver el documentoCortex Pruni Africanae
Ver el documentoCortex Rhamni Purshianae
Ver el documentoFlos Sambuci
Ver el documentoRadix Senegae
Ver el documentoFructus Serenoae Repentis
Ver el documentoFructus Silybi Mariae
Ver el documentoHerba Tanaceti Parthenii
Ver el documentoRadix Urticae
Ver el documentoFolium Uvae Ursi
Ver el documentoAnnex: Participants in the Second WHO Consultation on Selected Medicinal Plants

Folium et Cortex Hamamelidis


Folium et Cortex Hamamelidis consists of the dried or fresh leaves and/or the dried bark of Hamamelis virginiana L. (Hamamelidaceae).

Folium Hamamelidis consists of the dried (1, 2) or fresh leaves (3), and Cortex Hamamelidis consists of the dried bark of the trunk and twigs of Hamamelis virginiana L. (2, 4).


Hamamelis androgynaWalt., H. carolinianaWalt., H. corylifolia Moench., H. Dentata Moench., H. dioica Walt., H. estivalis Raf., H. macrophylla Pursh., H. nigra Raf., H. parvifolia Raf., H. rotundifolia Raf., H. virginata sic, H. virginiae L., H. virginiana ssp. parvifolia Nutt., H. virginica L., Trilopus dentata Raf., T. estivalis Raf., T. Nigra Raf., T. parvifolia Raf., T. rotundifolia Raf., T. virginica Raf. (5, 6).

Selected vernacular names

Amamelide, Amerikamansaku, cortice de hamamelis, feuilles d’hamamélis, feuilles du noisetier de la sorcière, folhas de hamamelis, hamamelis, hamamélis de virginie, Hexenhasel, magician’s rod, noisetier de sorcière, oczar, pistachio nut, snapping hazelnut, spotted alders, striped alder, tobacco wood, varázsdió levél és kéreg, vilin virginsky, virginische Zaubernuss, virginischer Zauberstrauch, white hazel, winter bloom, witch hazel, Zauberhasel, Zaubernuss (5-8).

Geographical distribution

Indigenous to the Atlantic coast of North America, found in damp woods ranging from Nova Scotia to Florida and as far west as Texas (6, 8, 9).


A tall shrub or small tree, up to 4.6 m high. Branches highly branched. Leaves alternate, stipulate, short-petioled, unequilaterally ovate or rhomboid-ovate, with oblique base and sinuate or sinuate-dentate margin. Flowers thread-like, golden-yellow; appear in axillary clusters as leaves fall in autumn and at about the same time as fruits ripen from blossoms of the previous year. Fruit a 2-beaked, 2-celled, woody capsule dehiscing loculicidally from the top, each cell containing a single black seed (8, 10, 11).

Plant material of interest: dried and fresh leaves, dried bark

General appearance


Green or greenish-brown, often broken, crumpled and compressed into more or less compact masses. Lamina 5-12 cm long, 3-8 cm wide, broadly ovate to obovate; base oblique and asymmetric; apex acute or, rarely, obtuse; margins of lamina roughly crenate or dentate. Venation pinnate and prominent on the abaxial surface; usually 4-6 pairs of secondary veins attached to main vein, leaving at an acute angle and curving gently to marginal points where there are fine veins often at right angles to secondary veins (1).


Channelled, seldom quilled or in strips, up to 3 cm wide and 2 mm thick. Outer surface light yellowish-brown or reddish-brown, has thin, whitish or greyishbrown cork with numerous lenticels; inner surface yellowish-brown to reddishbrown, longitudinally striated. Fracture splintery and fibrous (9).

Organoleptic properties


Odour: slight; taste: astringent, slightly aromatic, bitter (8).


Odourless; taste: strongly astringent, slightly bitter (2, 9).

Microscopic characteristics


Upper epidermis of leaf composed of slightly elongated cells with straight to slightly sinuous walls; walls moderately and sometimes unevenly thickened; no stomata; underlying palisade cells fairly small and distinct. Lower epidermis composed of polygonal cells with very sinuous outline; walls thinner and more uniform than those of upper epidermis; paracytic stomata fairly numerous but rather faint and indistinct; underlying cells of spongy mesophyll frequently brown, appear as clearly defined honeycomb network. Covering trichomes characteristic, stellate, found fragmented, occasionally entire, composed of 4-12 elongated, conical cells united at their bases to form a radiating structure; each cell has moderately and slightly unevenly thickened wall which is slightly lignified. Linear idioblasts, composed of lignified cells, found scattered across entire thickness of lamina. Prismatic calcium oxalate crystals scattered, occasionally found in clusters, as well as forming a sheath (12).


Sclereids abundant, vary considerably in size, are of 2 types: rounded to oval, or subrectangular; heavily thickened, usually in groups of just 2 or 3 cells, but smaller cells often form larger groups; walls have numerous, conspicuous branched pits and striations, particularly in the larger cells; other type of sclereids more regular in size and form, frequently found associated with the cork, occurring as a layer of small, polygonal cells with no intercellular spaces. Fibres occur in groups surrounded by a sheath of prismatic calcium oxalate crystals; individual fibres very thick-walled and lignified with indistinct lumen with calcium oxalate prismatic crystals scattered as well as in the parenchyma surrounding the fibres. Crystals also occasionally found associated with thickerwalled sclereids; crystals fairly uniform in size, although a few very large prisms may occur. Parenchyma cells thin-walled, several filled with dark brown contents. Medullary rays uniseriate, composed of rounded cells with slightly thickened walls. Cork cells thin-walled and polygonal. Fragments of lignified xylem tissue from adherent wood infrequent and consist of narrow tracheids with conspicuous bordered pits, accompanied by thin-walled fibres and pitted medullary ray cells. Starch grains rare; a few small, spherical grains may be found in some parenchymatous cells (12).

Powdered plant material


Brownish-green; fragments of adaxial epidermis with wavy anticlinal walls; abaxial epidermis with stomata, some paracytic, others atypical; covering trichomes, stellate, either entire or broken, composed of 4-12 cells united at their bases; cells elongated and conical, usually up to 250 µm long, thick-walled with clearly visible lumen with often brown contents. Fibres lignified and thickwalled, isolated or in groups; accompanied by sheath of prismatic calcium oxalate crystals. Parenchymatous palisade cells small and cylindrical; irregularshaped cells of spongy mesophyll; sclereids, frequently enlarged at one or both ends, 150-180 µm long, whole or fragmented; fragments of annular or spiral vessels; isolated prismatic calcium oxalate crystals (1).


Masses of brownish or yellowish cork cells, some lignified; groups of parenchyma cells with tannin or small starch grains; strands of lignified bast; tracheae with bordered pores; strongly lignified wood fibres with slit-like or bordered pores; crystal fibres containing monoclinic prismatic calcium oxalate crystals (up to 40 µm in length) (13).

General identity tests

Macroscopic and microscopic examinations (1), thin-layer chromatography (1, 2) and high-performance liquid chromatography (5) for characteristic tannin constituents.

Purity tests


Tests for specific microorganisms and microbial contamination limits are as described in the WHO guidelines on quality control methods for medicinal plants (14).

Foreign organic matter


Not more than 7% stems, and not more than 2% other foreign matter (1).


Not more than 2% foreign matter (2, 4).

Total ash


Not more than 7% (1).


Not more than 6% (2).

Acid-insoluble ash


Not more than 2% (1).


Not more than 1.5% (2).

Alcohol-soluble extractive


To be established in accordance with national requirements.


Not less than 20% using 45% alcohol (2).

Loss on drying


Not more than 10% (1).


Not more than 12% (4).

Pesticide residues

The recommended maximum limit of aldrin and dieldrin is not more than 0.05 mg/kg (15). For other pesticides, see the European pharmacopoeia (15), and the WHO guidelines on quality control methods for medicinal plants (14) and pesticide residues (16).

Heavy metals

For maximum limits and analysis of heavy metals, consult the WHO guidelines on quality control methods for medicinal plants (14).

Radioactive residues

Where applicable, consult the WHO guidelines on quality control methods for medicinal plants (14) for the analysis of radioactive isotopes.

Other purity tests

Folium and Cortex

Chemical, sulfated ash and water-soluble extractive tests to be established in accordance with national requirements.


Alcohol-soluble extractive test to be established in accordance with national requirements.

Chemical assays

Folium: contains not less than 3% tannins (1). Cortex: contains not less than 4% tannins (4). Thin-layer chromatography is used for qualitative and quantitative analysis of tannins (1). A high-performance liquid chromatography method for quantitative analysis of condensed and hydrolysable tannins has been developed (17, 18).

Major chemical constituents

The major constituents of the dried leaf and bark are tannins (up to 10%). Both hydrolysable and condensed tannins are present, with the latter predominating (9, 11, 19). Folium tannins are a mixture of gallic acid (10%), hydrolysable hamamelitannin (1.5%) and condensed proanthocyanidins (88.5%) (17). Cortex tannins are similar qualitatively, but have a much higher hamamelitannin level (up to 65% of a hydroalcoholic extract) (11).

The structures of gallic acid, hamamelitannin and condensed proanthocyanidins are presented below. gallic acid hamamelitannin

gallic acid




n = 0, R = H


n = 0, R = OH

Medicinal uses

Uses supported by clinical data

Topically for minor skin lesions, bruises and sprains (3, 5, 20), local inflammation of the skin and mucous membranes (3, 5, 20-24), haemorrhoids (3, 5, 20, 25-28) and varicose veins (3).

Uses described in pharmacopoeias and in traditional systems of medicine

Topically as a haemostat (27).

Uses described in folk medicine, not supported by experimental or clinical data

Treatment of colitis, diarrhoea, dysentery, dysmenorrhoea, eye inflammations, haematuria, kidney pains, neuralgia, nosebleeds and excessive menstruation. Also as a tonic (6, 7, 19).


Experimental pharmacology

Astringent activity

The phenolic constituents of Folium et Cortex Hamamelidis, particularly the tannins (e.g. hamamelitannin), aldehydes and oligomeric proanthocyanidins, are responsible for its astringent activity (6, 18, 29, 30). Similar to other astringent drugs, application of Hamamelidis1 preparations to the skin and mucosa in low concentrations sealed cell membranes and reduced capillary permeability (6, 30). Higher concentrations precipitated proteins and thickened colloidal tissue, forming a thin membrane in the wound region, and slightly compressed the skin tissue beneath it (6). Alcohol extracts of Hamamelidis had strong astringent action, with the bark extract being slightly superior to the leaf extract (31).

1 Refers to Folium et Cortex Hamamelidis.

The healing effect of Hamamelidis distillate was compared with hydrogen peroxide on skin damaged by application of dichlorodiethyl sulfide (mustard gas) in various animal models. The distillate was more effective than hydrogen peroxide in reducing the occurrence of pus in the affected skin areas. Furthermore, subsequent treatment of the purulent skin areas with a 20% Hamamelidis ointment reduced the incidence of suppuration as compared with hydrogen peroxide treatment (6, 32).

Venotonic activity

The venotonic effects of leaf preparations (steam distillate, tincture or alcohol extract) were tested by measuring the blood supply to the rear paw of rabbits (33). A decrease in blood supply was observed after intra-arterial administration of the distillate. This effect was not influenced by concomitant administration of adrenergic, adrenolytic or myotonic drugs (33-35).

Antibacterial activity

An aqueous extract of the leaves inhibited the growth in vitro of Escherichia coli (MIC 0.4 mg/ml), Staphylococcus aureus (MIC 0.4 mg/ml), Bacillus subtilis (MIC 1.1mg/ml) and Enterococcus faecalis (MIC 3.0mg/ml). Aqueous extracts of the bark inhibited the growth in vitro of Escherichia coli, Staphylococcus aureus, Bacillus subtilis and Enterococcus faecalis (MIC for all 10.0 mg/ml) (36).

Antioxidant activity

Hamamelitannin inhibited the production of superoxide anion radicals (IC50 1.38 µmol/l) and hydroxyl radicals (IC50 5.46 µmol/l), as measured by electron spin resonance spectrometry (37, 38). Hamamelitannin also suppressed the depolymerization of hyaluronic acid and protected human dermal fibroblasts against damage induced by superoxide anion radicals (at concentrations of 1 µmol/l and 10 µmol/l, respectively) (37). Hamamelitannin and gallic acid protected murine dermal fibroblasts against damage induced by superoxide anion radicals (IC50 1.31 µmol/l and 1.01 µmol/l, respectively) (38). Both tannins had free radical scavenging activity. For superoxide anion scavenging, the IC50 was 1.31 µmol/l for hamamelitannin and 1.01 µmol/l for gallic acid, compared with 23.31 µmol/l for ascorbic acid. For hydroxyl radical scavenging, the IC50 was 5.46 µmol/l for hamamelitannin and 78.04 µmol/l for gallic acid. For singlet oxygen scavenging, the IC50 was 45.51 µmol/l for hamamelitannin and 69.81 µmol/l for gallic acid (39).

Anti-inflammatory activity

Hamamelidis extracts and isolated chemical constituents have antiinflammatory activity both in vitro and in vivo. Intraperitoneal administration of a 70% ethanol extract of the leaves (200 mg/kg body weight) significantly inhibited the chronic phase of carrageenan-induced rat footpad oedema (40). Hamamelitannin and galloylated proanthocyanidins isolated from Hamamelidis are potent inhibitors of 5-lipoxygenase (IC50 range 1.0-18.7 µg/ml). Topical application of a hydroalcoholic extract of the bark (250 μg/ml) inhibited croton oil-induced ear oedema in mice. In addition to anti-inflammatory activity, this study demonstrated that the proanthocyanidin fraction of the hydroalcoholic extract was active against herpes simplex virus type 1 (ED50 11 µg/ml), and also inhibited α-glucosidase (ED50 0.35 µg/ml) and human leukocyte elastase (ED50 1.4 µg/ml) (41).

Clinical pharmacology

Anorectal complaints

The astringent properties of Hamamelidis extracts have led to their use in ointments and suppositories for the treatment of anorectal complaints, such as haemorrhoids (25-27). In a clinical study without controls of 75 patients with acute stage 1 haemorrhoidal symptoms, the efficacy of rectal ointments containing either a Hamamelidis fluidextract or bismuth subgallate was assessed. After application of either ointment twice daily for 3 days, significant improvement was observed in pruritus, burning sensation and pain (P < 0.001). Marked recovery was noted after 3 weeks of therapy (25). A randomized, double-blind trial compared the efficacy of rectal ointments containing either a Hamamelidis fluidextract, bismuth subgallate or a local anaesthetic in the treatment of 90 patients with acute stage 1 haemorrhoidal symptoms. The local anaesthetic was present in two control ointments which also contained either policresulen or fluocinolone acetonide. After 21 days of treatment, all four ointments were equally effective in improving pruritus, bleeding, burning sensation and pain (26).

The efficacy of a Hamamelidis ointment containing 25 g aqueous distillate/100 g ointment base (equivalent to about 4 g drug) was compared to a Hamamelidis reference preparation in a study without controls of 70 patients with various anorectal complaints. Preparations were applied to the affected skin or transitional mucosa three times daily either alone or in combination with sclerotherapy. After 4 weeks of treatment, symptoms such as pruritus, burning sensation and pain were eliminated in 60% of the patients treated with the Hamamelidis ointment (28).

Anti-inflammatory activity

The anti-inflammatory efficacy of an aftersun lotion containing 10% Aqua Hamamelidis was compared with that of two Hamamelidis-free aftersun lotions in 30 healthy volunteers. Each volunteer received four doses of ultraviolet B in a modified ultraviolet B erythema test. Chromametry and visual scoring were used to determine the degree of erythema at 7, 24 and 48 hours after irradiation. The lotion containing Hamamelidis suppressed erythema by 20% at 7 hours and by 27% at 48 hours, whereas the degree of suppression seen with the Hamamelidis-free lotions was 11% and 15%, respectively (42).

A randomized, double-blind study of 48 patients assessed the antiinflammatory efficacy of topical application of a Hamamelidis distillate in a phospholipid-containing vehicle, hydrocortisone, camomile and four drug-free vehicle-based preparations. Erythema induced by ultraviolet light or repeated stripping of the skin with adhesive tape was suppressed only by the Hamamelidis preparation (0.64 mg or 2.5 mg Hamamelidis ketone per 100 g vehicle) and hydrocortisone cream (1%). However, the hydrocortisone cream was superior to all other preparations tested (21).


A randomized, placebo-controlled study assessed the vasoconstrictive effects of an aqueous propylene glycol extract of Hamamelidis in 30 healthy volunteers. The extract produced a reduction in skin temperature as compared with the placebo (6, 43). The anti-inflammatory effects of a Hamamelidis ointment containing 25 g aqueous distillate/100 g ointment base (about 4 g drug) were analysed in five patients with dermatoses and 22 healthy volunteers. Fluvography measurements indicated that in both groups the ointment reduced the thermal conductivity of the skin due to vasoconstriction, suggesting a mild antiinflammatory activity. These data were confirmed by transcutaneous oxygen measurements (44).


A randomized, double-blind, placebo-controlled trial compared the efficacy of three creams containing either a Hamamelidis distillate, 0.5% hydrocortisone or a drug-free vehicle in the symptomatic treatment of 72 patients with moderately severe atopic eczema. All treatments reduced the incidence of itching, scaling and erythema after 1 week of treatment: the cream containing Hamamelidis distillate was no more effective than that containing the placebo (45).

The efficacy of two Hamamelidis ointments (differing only in the ointment base), containing 25 g aqueous distillate/100 g ointment base (equivalent to about 4 g drug), for the treatment of endogenous eczema (neurodermatitis) and toxic degenerative eczema (attrition eczema) was compared in a placebocontrolled, double-blind study (the placebo was not described). Symptomatic improvements in itching, redness, burning sensation and desquamation of the skin were observed in the 36 patients with endogenous eczema (neurodermatitis) with both Hamamelidis preparations after treatment for 39 days. Eighty patients with toxic degenerative eczema (attrition eczema) treated with the Hamamelidis ointments showed improvements in rough skin, redness, burning sensation and desquamation of the skin after 28 days of treatment (23).

A randomized, double-blind comparison study assessed the efficacy of ointments containing either a standardized extract of the dried leaves or bufexamac in the treatment of 22 patients with bilateral, moderately severe endogenous eczema (neurodermatitis). Patients were treated three times daily for an average of 17 days. Comparison of the patients’ forearms showed that both treatments reduced the severity of symptoms such as desquamation of the skin, redness, itching and lichenification, with desquamation showing the highest reduction (55%). No differences were observed in the global assessment of the therapy or the severity of symptoms between treatments (24).

In a pilot study of 37 patients with endogenous eczema (neurodermatitis), a cream containing a Hamamelidis leaf extract was applied twice daily for 2 weeks. Following treatment, considerable improvement in symptoms such as inflammation and itching was noted in 24 patients (46).

Analgesic activity

In a randomized clinical trial involving 266 patients undergoing episiotomy, the efficacy of three analgesic treatments was investigated to determine their effects on pain, bruising and oedematous swelling. The treatments tested were local application of: a cream containing Hamamelidis water BPC 1973; a reference cream containing 1% hydrocortisone and a local anaesthetic; and ice packs. Oral paracetamol and salt baths were also used as needed. The efficacy of all three analgesic treatments appeared to be equal (22).

Antiviral activity

The efficacy and safety of an ointment prepared with a special extract from the bark was assessed in a randomized, double-blind, placebo-controlled study for the treatment of herpes labialis infection. Thirty-four patients were treated within 48 hours of recurrence of symptoms, and treatment (daily) lasted for 8 days. By the end of the therapy, the size of the inflamed area was significantly reduced in patients treated with the Cortex Hamamelidis ointment as compared with placebo treatment (P = 0.022) (47).


No information available.


No information available.


Carcinogenesis, mutagenesis, impairment of fertility

Aqueous extracts of the dried leaves were not carcinogenic when administered subcutaneously to rodents (10 mg/animal) (48).

Other precautions

No information available on general precautions or precautions concerning drug interactions; drug and laboratory test interactions; teratogenic and nonteratogenic effects in pregnancy; nursing mothers; or paediatric use. Therefore, Folium et Cortex Hamamelidis should not be administered during pregnancy or lactation or to children without medical supervision.

Adverse reactions

Allergic contact dermatitis may occur in sensitive individuals (49, 50).

Dosage forms

Dried leaves and bark for decoctions; steam distillate, ointment and suppositories (3, 9). Fresh leaves and twigs are collected in the spring and early summer to make a steam distillate (3). Store in a well-closed container, protected from light (19).


(Unless otherwise indicated)
External use: steam distillate, undiluted or diluted 1:3 with water to make poultices; 20-30% in semisolid preparations (3). Extracts: in semisolid and liquid preparations corresponding to 5-10% of the crude drug (3, 5). Crude drug: decoctions from 5-10 g to 1 cup (250 ml) water for poultices and wound irrigation (3, 5). Rectal suppositories: 1-3 times daily the quantity of a preparation corresponding to 0.1-1.0 g crude drug, use Hamamelidis water undiluted or diluted 1:3 with water (3, 5). Other preparations: several times daily, corresponding to 0.1-1.0 g drug in preparations, or witch hazel water undiluted or diluted with water (3).


1. European pharmacopoeia, 3rd ed., Suppl. 2000. Strasbourg, Council of Europe, 1999.

2. British herbal pharmacopoeia. London, British Herbal Medicine Association, 1996.

3. Blumenthal M et al., eds. The complete German Commission E monographs. Austin, TX, American Botanical Council, 1998.

4. Deutscher Arzneimittel-Codex. Stuttgart, Govi-Verlag, 1998.

5. Blaschek W et al., eds. Hagers Handbuch der pharmazeutischen Praxis. Folgeband 2: Drogen A-K, 5th ed. Berlin, Springer-Verlag, 1998.

6. Laux P, Oschmann R. Die Zaubernuss - Hamamelis virginiana L. Zeitschrift für Phytotherapie, 1993, 14:155-166.

7. Farnsworth NR, ed. NAPRALERT database. Chicago, University of Illinois at Chicago, IL, February 9, 1998 production (an online database available directly through the University of Illinois at Chicago or through the Scientific and Technical Network [STN] of Chemical Abstracts Services).

8. Youngken HW. Textbook of pharmacognosy, 6th ed. Philadelphia, PA, Blakiston, 1950.

9. Bisset NG. Herbal drugs and phytopharmaceuticals. Boca Raton, FL, CRC Press, 1994.

10. Tyler VE. The honest herbal. New York, NY, Pharmaceutical Product Press, 1993.

11. Bruneton J. Pharmacognosy, phytochemistry, medicinal plants. Paris, Lavoisier, 1995.

12. Jackson BP, Snowdon DK. Atlas of microscopy of medicinal plants, culinary herbs and spices. Boca Raton, FL, CRC Press, 1990.

13. Gathercoal EN, Wirth EH, eds. Pharmacognosy. Philadelphia, Lea & Febiger, 1936.

14. Quality control methods for medicinal plant materials. Geneva, World Health Organization, 1998.

15. European pharmacopoeia, 3rd ed. Strasbourg, Council of Europe, 1996.

16. Guidelines for predicting dietary intake of pesticide residues, 2nd rev. ed. Geneva, World Health Organization, 1997 (document WHO/FSF/FOS/97.7).

17. Vennat B et al. Tannins from Hamamelis virginiana: identification of proanthocyanidins and hamamelitannin quantification in leaf, bark, and stem extracts. Planta Medica, 1988, 54:454-457.

18. Vennat B et al. Hamamelis virginiana: identification and assay of proanthocyanidins, phenolic acids and flavonoids in leaf extracts. Pharmaceutica Acta Helvetiae, 1992, 67:11-14.

19. Newall CA, Anderson LA, Phillipson JD. Herbal medicines: a guide for healthcare professionals. London, The Pharmaceutical Press, 1996.

20. ESCOP monographs on the medicinal uses of plant drugs. Fascicule 5. Devon, European Scientific Cooperative on Phytotherapy, 1997.

21. Korting HC et al. Anti-inflammatory activity of Hamamelis distillate applied topically to the skin. European Journal of Clinical Pharmacology, 1993, 44:315-318.

22. Moore W, James DK. A random trial of three topical analgesic agents in the treatment of episiotomy pain following instrumental vaginal delivery. Journal of Obstetrics and Gynaecology, 1989, 10:35-39.

23. Pfister R. Zur Problematik der Behandlung und Nachbehandlung chronischer Dermatosen. Eine klinische Studie über Hametum Salbe. Fortschritte der Medizin, 1981, 99:1264-1268.

24. Swoboda M, Meurer J. Therapie von Neurodermitis mit Hamamelis virginiana Extrakt in Salbenform. Zeitschrift für Phytotherapie, 1991, 12:114-117.

25. Knoch HG. Hämorrhoiden ersten Grades: Wirksamkeit einer Salbe auf pflanzlicher Basis. Münchener Medizinische Wochenschrift, 1991, 133:481-484.

26. Knoch HG et al. Salbenbehandlung von Hämorrhoiden ersten Grades. Fortschritte der Medizin, 1992, 110:135-138.

27. Reynolds JEF, Prasad AB. Martindale, the extra pharmacopoeia, 30th ed. London, The Pharmaceutical Press, 1996.

28. Steinhart GP. Anorektale Beschwerden: viele Symptome und was tun? Ärztliche Praxis, 1982, 34:963-964.

29. Hänsel R. Phytopharmaka, Grundlagen und Praxis. Vol. 2. Berlin, Springer-Verlag, 1991.

30. Steinegger E, Hansel R. Pharmakognosie. Berlin, Springer, 1992.

31. Grascza L. Adstringierende Wirkung von Phytopharmaka. Deutsche Apotheker Zeitung, 1987, 44:2256-2258.

32. Kesser E et al. Therapie von Senfgasschädigungen der Haut. Archives of Experimental Pathology and Pharmacy, 1936, 180:557.

33. Bernard P et al. Valeur pharmacodynamique toniveineuse des préparations galéniques à base de feuilles d’Hamamelis. Journal de Pharmacie de Belgique, 1972, 4:505-512.

34. Balansard P et al. Méthode d’étude quantitative de l’action veinotrope. Thérapie, 1970, 25:675-682.

35. Balansard P et al. Action toniveineuse d’un extrait purifié d’Hamamelis virginiana. Thérapie, 1972, 27:793-799.

36. Brantner A, Grein E. Antibacterial activity of plant extracts used externally in traditional medicine. Journal of Ethnopharmacology, 1994, 44:35-40.

37. Masaki H et al. Evaluation of superoxide scavenging activities of Hamamelis extract and hamamelitannin. Free Radical Research Communications, 1993, 19:333-340.

38. Masaki H et al. Hamamelitannin as a new potent active oxygen scavenger. Phytochemistry, 1994, 37:337-343.

39. Masaki H et al. Protective activity of hamamelitannin on cell damage induced by superoxide anion radicals in murine dermal fibroblasts. Biological and Pharmaceutical Bulletin, 1995, 18:59-63.

40. Duwiejua M et al. Anti-inflammatory activity of Polygonum bistorta, Guaiacum officinale and Hamamelis virginiana in rats. Journal of Pharmacy and Pharmacology, 1993, 46:286-290.

41. Erdelmeier CAJ et al. Antiviral and antiphlogistic activities of Hamamelis virginiana bark. Planta Medica, 1996, 62:241-245.

42. Hughes-Formella BJ et al. Anti-inflammatory effect of Hamamelidis lotion in a UVB erythema test. Dermatology, 1998, 196:316-322.

43. Diemunsch AM, Mathis C. S.T.P. Effet vasoconstricteur de l’hamamélis en application externe. Pharma, 1987, 3:111-114.

44. Sorkin B. Hametumsalbe, eine kortikoidfreie antiinflammatorische Salbe. Physikalische Medizin und Rehabilitation, 1980, 21:53-57.

45. Korting HC et al. Comparative efficacy of Hamamelis distillate and hydrocortisone cream in atopic eczema. European Journal of Clinical Pharmacology, 1995, 48: 461-465.

46. Wokalek H. Zur Bedeutung epidermaler Lipide und des Arachidonsäurestoffwechsels bei feuilles d’hamamelis. Journal de Pharmacie de Belgique, 1993, 27: 498-506.

47. Baumgärtner M et al. Hamamelis-Spezialextrakt zur lokalen Behandlung des Herpes labialis, eine plazebokontrollierte Doppelblindstudie. Zeitschrift für Allgemeine Medizin, 1998, 74:158-161.

48. Kapadia GJ et al. Carcinogenicity of some folk medicinal herbs in rats. Journal of the National Cancer Institute, 1978, 60:683-686.

49. Bruynzeel DP et al. Contact sensitization by alternative topical medicaments containing plant extracts. Contact Dermatitis, 1992, 27:278-279.

50. Granlund H. Contact allergy to witch hazel. Contact Dermatitis, 1994, 31:195.


Ir a la sección anterior Ir a la siguiente sección
Última actualización: le 4 mayo 2012